Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvadaxistat for Cognitive Impairment in Schizophrenia
NCT05182476Phase 2Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of luvadaxistat in schizophrenia, sponsored by Neurocrine Biosciences. Started Dec 2021; status: terminated.
02
Drugs
luvadaxistat
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05182476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182476.